跳到正文
原文
MedTech Dive 器械媒体· Elise Reuter·· 2026-10-02AI 评分40

FDA 遴选首批 5 家 READI-Home 创新挑战参与者

FDA selects first 5 participants for READI-Home initiative

AI 导读

FDA 公布 READI-Home 家庭医疗器械创新挑战首批 5 家参与者,旨在开发减少医院再入院率的家用设备。入选企业包括 BD、Epitel、Prapela、Current Health 和 Skribe Medical,涵盖血检、癫痫监测、婴儿护理及心功能评估等场景。

正文

An article from site logo

Dive Brief

The innovation challenge is focused on developing home devices that could help reduce hospital readmissions.

Published Oct. 1, 2026

Elise Reuter's headshot

A sign for the Food And Drug Administration is seen

A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020, in Silver Spring, Maryland. Sarah Silbiger via Getty Images

Dive Brief:

  • The Food and Drug Administration has selected the first participants for an innovation challenge for home devices that could be used to reduce hospital readmissions.
  • The first five participants include large medtech firm BD, wearable EEG startup Epitel, infant care company Prapela, Current Health, a company making software for cancer care, and Skribe Medical, which makes a device to assess cardiac function.
  • The FDA’s device center plans to choose a total of nine participants by Dec. 4 for the challenge, called Reducing Readmissions through Device Innovation for the Home, or READI-Home. The selected manufacturers will have opportunities for early engagement with the FDA, including feedback on device design and testing, and demonstrations at the agency’s research facilities.

Dive Insight:

The five participants address a variety of health needs. Epitel makes a wireless wearable EEG system used after a person is discharged from the hospital. The device is intended for people 6 years and older who are being assessed for seizures, poor sleep or delirium. 

Prapela makes a crib mattress that provides gentle, randomized vibrations while an infant is sleeping to reduce the frequency, duration and severity of hypoxemic and bradycardic episodes in babies with single-ventricle heart disease. Prapela intends for the device to be used in between surgeries to treat the condition, which can be a high-risk period.

BD is entering the program with a home self-collection blood sampling kit for adults. It’s intended to allow adults to collect a capillary blood specimen at home for subsequent testing.

Current Health has developed artificial intelligence-enabled software to help healthcare professionals identify the risk for cancer patients undergoing chimeric antigen receptor T-cell, or CAR-T, therapy. One of the risks of CAR-T therapy is cytokine release syndrome, a serious immune reaction. Current’s solution would allow people undergoing the treatment to be monitored in a home setting. 

Finally, Skribe Medical has developed a wearable patch that patients or caregivers can use at home to estimate a key measure of heart function, left ventricular ejection fraction, the amount of blood pumped out with each heartbeat. The results are sent to a healthcare professional for interpretation. 

The READI-Home Innovation Challenge is part of the FDA’s Home as a Healthcare Hub initiative, which was launched by Center for Devices and Radiological Health Director Michelle Tarver in 2024 to consider people’s lived environments in device design with the goal of improving health equity.

来源:MedTech Dive 器械媒体 · medtechdive.com